2026-04-29T22:57:50Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/152072024-09-27T09:08:53Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Hoffmann, Jedrzej author Richardson, Gavin author Haendeler, Judith author Altschmied, Joachim author Andres, Vicente author Spyridopoulos, Ioakim author 2021 Shortened telomeres have been linked to numerous chronic diseases, most importantly coronary artery disease, but the underlying mechanisms remain ill defined. Loss-of-function mutations and deletions in telomerase both accelerate telomere shortening but do not necessarily lead to a clinical phenotype associated with atherosclerosis, questioning the causal role of telomere length in cardiac pathology. The differential extranuclear functions of the 2 main components of telomerase, telomerase reverse transcriptase and telomerase RNA component, offer important clues about the complex relationship between telomere length and cardiovascular pathology. In this review, we critically discuss relevant preclinical models, genetic disorders, and clinical studies to elucidate the impact of telomerase in cardiovascular disease and its potential role as a therapeutic target. We suggest that the antioxidative function of mitochondrial telomerase reverse transcriptase might be atheroprotective, making it a potential target for clinical trials. Graphic Abstract: A graphic abstract is available for this article. Arterioscler Thromb Vasc Biol. 2021 Mar;41(3):1047-1061. 10.1161/ATVBAHA.120.315695 1524-4636 Arteriosclerosis, thrombosis, and vascular biology 33504179 http://hdl.handle.net/20.500.12105/15207 Telomerase as a Therapeutic Target in Cardiovascular Disease.